Xencor | XNCR - Gross Profit On Sales


Xencor reported $21M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Amgen USD 6.48B 307M Sep/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
AstraZeneca USD 12.39B 5M Dec/2025
Biogen USD 1.65B 34.6M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Cytokinetics USD 17.76M 15.82M Dec/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
J&J USD 16.6B 118M Dec/2025
Karyopharm Therapeutics USD 32.6M 63.38M Dec/2025
MacroGenics USD 31.11M 30.14M Dec/2025
Merck USD 13.42B 431M Sep/2025
Novartis USD 10.25B 570M Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Xencor USD 21M 22.61M Sep/2025